Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
Become a Member | Sign in
Home>News>This Article

VelaDx Signs Agreement with Life Technologies to Develop IVD Tests on Ion PGM Sequencer

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
Semiconductor sequencing brings unprecedented power to diagnostic tests to transform personalized medicine.

Vela Diagnostics to leverage fast-selling Ion PGM Sequencer to capture untapped global market for fast, simple, affordable sequencing-based diagnostics.

Life Technologies Corporation and VelaDx have entered into a license and supply agreement that will give VelaDx rights to develop and market next generation sequencing-based, in vitro diagnostic tests on the Ion Personal Genome Machine™ (PGM™) platform.  VelaDx will seek approvals from global regulatory authorities for clinical diagnostic tests in oncology and infectious disease.

Vela Diagnostics chose the Ion PGM™ System because of its speed, simplicity and flexibility, and because it's complementary to Vela's Sentosa™ workflow and its menu of qPCR assay kits. Both Ion's PGM™ and Vela's Sentosa™ systems can operate on a menu of single-indication tests or multiple-indication panels that can easily be implemented in virtually any laboratory. A seamless, bi-directional data communication with laboratory information systems between the Ion PGM™ and Sentosa™ systems will maintain the accuracy of data and improve the efficiency of the laboratory workflow.

"Our agreement with Life Technologies puts Vela Diagnostics at the cutting edge position in medicine," said Vela CEO, Michael Tillmann. "The Ion PGM™ System will support Vela's strategy to improve laboratory efficiency and bring new innovative tests to our customers to help improve treatment decisions for patients."

Target markets addressed by VelaDx are attractive and growing quickly.

A recent PiperJaffray report estimates the current infectious disease market to be  $2 billion annually and growing by more than 8 percent.  United Health Group predicts the genetic testing market will grow to $25 billion by 2021.

"Semiconductor sequencing is a transformative technology that can make diagnostic tests faster — a one-day turnaround — and more informative, helping doctors around the world save lives and make personalized medicine a reality," said Ion Torrent President and COO Gregg Fergus. "The founders and management team at Vela Diagnostics have a proven track record of first-mover success in the diagnostic marketplace and are ideal partners to introduce tests in the important clinical areas they have licensed."

The Ion PGM™ Sequencer uses a completely novel sequencing technology that directly translates the language of chemistry into the binary language of computers on a semiconductor chip. This new approach has democratized sequencing, making it far more accessible than ever before. The system can perform a sequencing run in just 90 minutes and automated sample prep makes it easy for a lab technician of any experience level to operate. The cost of the Ion PGM™ System is just a fraction of other systems and accuracy is at a Q30 quality level, both of which are helping to rapidly drive adoption. More than 1,000 units were sold in the system's first 18 months on the market.  Life Technologies plans to seek clearance for the Ion PGM System from the FDA as well as approval from other global regulatory agencies."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies' Ion AmpliSeq™ Exome Program Adds 12 New Members
With more than 30 members the program is the largest network of next generation-based exome sequencing providers in the world.
Friday, December 20, 2013
KACST Partners with Life Tech in The Saudi Human Genome Program
Program aims to analyze 100,000 human genomes to identify the causes of disease in the population of the Kingdom of Saudi Arabia and the Arab world.
Monday, December 09, 2013
BGI Partners with Life Technologies
World's largest genome center to purchase 50 Ion Proton™ Sequencers from Life Technologies.
Tuesday, October 22, 2013
Life Technologies Expand Ion AmpliSeq™ Exome Certified Service Provider Program
Due to increased demand the program is expanding to include eleven new members.
Wednesday, October 09, 2013
TriCore Reference Laboratories Named First NGS Center of Excellence by Life Technologies
Collaborative partnership designed to accelerate clinical research in the Southwest using advanced NGS oncology panels.
Thursday, September 19, 2013
Life Technologies Signs Five-Year Agreement with the FDA
The agreement aims to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Tuesday, July 30, 2013
Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Acquires Life Science Korea
The acquisition strengthens Life Tech's go-direct strategy in South Korea.
Friday, June 14, 2013
Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
Life Technologies Corporation announced that the new Center for Personalized Medicine at Roswell Park Cancer Institute has purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ sequencers.
Thursday, February 21, 2013
Life Technologies Bolsters its 60 Percent Market Share Lead in Benchtop Sequencers
More than 90 peer-reviewed papers and the world's largest online sequencing community reflects broad adoption of Ion Torrent™ technology.
Wednesday, February 20, 2013
Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Products
Life's Applied Biosystems Dx Genetic Analyzer and SeCore® kits constitute first sequence-based system cleared for HLA typing.
Tuesday, February 12, 2013
Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a Clinical Genomics Company
Spinoff venture will develop genomic sequencing solutions utilizing Ion Torrent technology for clinical applications.
Thursday, January 10, 2013
Life Technologies Announces Third Quarter 2012 Results
Revenue for the third quarter was $911 million, a decrease of 1.9 percent over the $929 million reported for the third quarter of 2011. Excluding the impact of currency, revenue growth for the quarter was 1.4 percent compared to the same period of the prior year.
Monday, November 05, 2012
Life Technologies Acquires Compendia Bioscience
Bioinformatics expertise will enable deeper engagement with established customer base of leading pharmaceutical companies.
Tuesday, October 09, 2012
Acquisition of Navigenics Expands Life Technologies' Capabilities
Addition of Navigenics' physician portal provides informatics to support patient management.
Thursday, July 19, 2012
Scientific News
Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
Carsten Flohr and his research group at St Thomas’s hospital, London are currently investigating the interaction between skin and gut microbiota in relation to the associated risk of atopic eczema (AE) and food allergy in infants.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.
Proteins Crucial to Loss of Hearing Identified
Proteins play key role in genes that help auditory hair cells grow.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.
Far-reaching Genetic Study of 1,000 UK People
300,000 gene variants from 1,000 people made publically available via F1000Research.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
Targeting DNA
Protein-based sensor could detect viral infection or kill cancer cells.
Genetic Sleuthing
Sabeti team applies Ebola methods to shed light on spread of Lassa fever.
Seeking “Gold Standard” Wastewater Treatments
Metagenomic analyses lend insights into how microbes break down wastewater contaminants.
Using Genetic Sequencing to Manage Cancer in Children
A team of scientists have investigated the feasibility of incorporating clinical sequencing information into the care of young cancer patients.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos